Curis Inc. Common Stock (CRIS)

FairStock Score: 53/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I look first for a durable business earning consistent profits. Curis is not that. It is a 20-employee clinical-stage oncology company whose filed FY2025 10-K shows revenue of $9.4M and a net loss of $7.6M, or diluted EPS of -$0.58. That was an improvement from FY2024, when revenue was $10.9M and net loss was $43.4M, and FY2023, when revenue was $10.0M and net loss was $47.4M. But the latest filed quarter, fiscal Q2 2026 ended 2026-06-30, still showed a net loss of $8.6M and diluted EPS of -$4.02. Trailing free cash flow is -$30.6M, a -127.3% FCF yield on the $24.0M market cap at the 2026-10-13 close. The balance sheet shows D/E of 0.22, but ROE is -693.93%, ROCE is -93.23%, and Altman Z is -95.16, all signs of severe financial fragility. The FairStock P/B is 0.25 and Graham Number is $14.07 with a 95.66% margin of safety, but those calculations are not meaningful when earnings are negative and cash is burning. There is no moat here in the Graham sense: no pricing power, no recurring revenue, no demonstrated profitability. The investment case rests entirely on clinical trial outcomes for Emavusertib and other pipeline assets. That is speculative, not value investing. At $0.61, the stock may look statistically cheap, but the business quality and financial health are poor. A value investor would need evidence of durable cash generation or a much stronger balance sheet before calling this a value opportunity.

In plain English: Curis is a very small healthcare company that studies experimental cancer drugs. It has lost money in each of the last four years, brings in only a few million dollars of revenue, and spends more cash than it takes in, so the business looks weak. The share price is low compared with some accounting measures, but those measures are hard to trust for a company that is not yet profitable.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer